Benefits of L-arginine on cardiovascular system

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 2, 2016, Pages 94-103

  Sudar Milovanovic, Emina ^a   Obradovic, Milan ^a   Jovanovic, Aleksandra ^a   Zaric, Bozidarka ^b   Zafirovic, Sonja ^a   Panic, Anastasija ^a   Radak, Djordje ^c   Isenovic, Esma R ^a,d  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Amino acid; Arginase; Cardiovascular disorders; Cardiovascular system; L Arg; NO; NOS

Indexed keywords

ACETYLCHOLINE; ADENOSINE DIPHOSPHATE; AGMATINE; ARGINASE; ARGININE; ARGININE DECARBOXYLASE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; BRADYKININ; CALMODULIN; CITRULLINE; CREATINE; CYCLIC GMP; DIMETHYLARGININASE; ENDOTHELIN 1; GLYCINE AMIDINOTRANSFERASE; GROWTH HORMONE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORNITHINE CARBAMOYLTRANSFERASE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; REACTIVE OXYGEN METABOLITE; TETRAHYDROBIOPTERIN; THROMBIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CHEMICAL STRUCTURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG METABOLISM; ENDOTHELIUM CELL; HEART FUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; METABOLISM;

ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; HUMANS; NITRIC OXIDE;

EID: 84949816844     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666151016125826     Document Type: Article

References (161)

1. Guoyao, W. Amino Acids: Biochemistry and Nutrition, Taylor & Francis Group 2013.
2. Luiking, Y. C.; Hallemeesch, M. M.; Lamers, W. H.; Deutz, N. E. The role of NOS2 and NOS3 in renal protein and arginine metabolism during early endotoxemia in mice. Am. J. Physiol. Renal. Physiol., 2005, 288(4), F816-822.
3. Flynn, N. E.; Meininger, C. J.; Haynes, T. E.; Wu, G. The metabolic basis of arginine nutrition and pharmacotherapy. Biomed. Pharmacother., 2002, 56(9), 427-438.
4. Wu, G.; Morris, S. M., Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J., 1998, 336(Pt 1), 1-17.
5. Boger, R. H.; Bode-Boger, S. M. The clinical pharmacology of L-arginine. Ann. Rev. Pharmacol. Toxicol., 2001, 41, 79-99.
6. Morris, S. M., Jr. Arginine metabolism in vascular biology and disease. Vasc Med., 2005, 10 Suppl 1, S83-87.
7. Tapiero, H.; Mathe, G.; Couvreur, P.; Tew, K. D. I. Arginine. Biomed. Pharmacother., 2002, 56(9), 439-445.
8. Sm, M. J. Arginine synthesis, metabolism and transport: regulators of nitric oxide synthesis, Marcel Dekker: New York, NY, 1998.
9. Stuehr, D. J. Structure-function aspects in the nitric oxide synthases. Ann. Rev. Pharmacol. Toxicol., 1997, 37, 339-359.
10. Wu, G.; Flynn, N. E.; Flynn, S. P.; Jolly, C. A.; Davis, P. K. Dietary protein or arginine deficiency impairs constitutive and inducible nitric oxide synthesis by young rats. J. Nutr., 1999, 129(7), 1347-1354.
11. Cylwik, D.; Mogielnicki, A.; Buczko, W. L-arginine and cardiovascular system. Pharmacol. Rep., 2005, 57(1), 14-22.
12. Giugliano, D.; Marfella, R.; Verrazzo, G.; Acampora, R.; Nappo, F.; Ziccardi, P.; Coppola, L.; D'Onofrio, F. L-arginine for testing endothelium-dependent vascular functions in health and disease. Am. J. Physiol., 1997, 273(3 Pt 1), E606-612.
13. Gryglewski, R. J.; Grodzinska, L.; Kostka-Trabka, E.; Korbut, R.; Bieroon, K.; Goszcz, A.; Slawinski, M. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien Klin Wochenschr. 1996, 108(4), 111-116.
14. Stief, T. W.; Weippert, M.; Kretschmer, V.; Renz, H. Arginine inhibits hemostasis activation. Thromb Res., 2001, 104(4), 265-274.
15. Bode-Boger, S. M.; Boger, R. H.; Kienke, S.; Bohme, M.; Phivthong-ngam, L.; Tsikas, D.; Frolich, J. C. Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc Res., 1998, 37(3), 756-764.
16. Kawabata, A.; Hata, T. Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat. Br. J. Pharmacol., 1996, 119(2), 346-350.
17. Tsao, P. S.; Theilmeier, G.; Singer, A. H.; Leung, L. L.; Cooke, J. P. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb., 1994, 14(10), 1529-1533.
18. M. N. Chatterjea; Shinde, R. Textbook of Medical Biochemistry, 8th Ed.; JP Medical 2012.
19. McKee, T. Biochemistry, McGraw-Hill Education: 1998.
20. Castillo, L.; Chapman, T. E.; Sanchez, M.; Yu, Y. M.; Burke, J. F.; Ajami, A. M.; Vogt, J.; Young, V. R. Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc. Natl. Acad. Sci. U.S.A., 1993, 90(16), 7749-7753.
21. Castillo, L.; Ajami, A.; Branch, S.; Chapman, T. E.; Yu, Y. M.; Burke, J. F.; Young, V. R. Plasma arginine kinetics in adult man: response to an arginine-free diet. Metabolism, 1994, 43(1), 114-122.
22. Wu, G.; Bazer, F. W.; Davis, T. A.; Kim, S. W.; Li, P.; Marc Rhoads, J.; Carey Satterfield, M.; Smith, S. B.; Spencer, T. E.; Yin, Y. Arginine metabolism and nutrition in growth, health and disease. Amino Acids, 2009, 37(1), 153-168.
23. Visek, W. J. Arginine needs, physiological state and usual diets. A reevaluation. J. Nutr., 1986, 116(1), 36-46.
24. Thornton, F. J.; Schaffer, M. R.; Barbul, A. Wound healing in sepsis and trauma. Shock, 1997, 8(6), 391-401.
25. King, D. E.; Mainous, A. G., III; Geesey, M. E. Variation in Larginine intake follow demographics and lifestyle factors that may impact cardiovascular disease risk. Nutr. Res., 2008, 28(1), 21-24.
26. Wu, G.; Collins, J.K.; Perkins-Veazie, P.; Siddiq, M.; Dolan, K.D.; Kelly, K.A.; Heaps, C.L.; Meininger, C.J. Dietary supplementation with watermelon pomace juice enhances arginine availability and ameliorates the metabolic syndrome in Zucker diabetic fatty rats. J. Nutr., 2007, 137(12), 2680-2685.
27. Ping, H. Z.; Long, Y. Y.; Lin, H. R.; Jun, L. T.; Qing, H. R.; Lan, L. Y.; Xin, W.; Qiang, L. Z.; Ce, W. W.; Hua, X.; Wu, G. Y.; Xi, T. L. Rice protein concentrate partially replaces dried whey in the diet for early-weaned piglets and improves their growth performance. J. Sci. Food Agric., 2008, 88(7), 1187-1193.
28. Featherston, W. R.; Rogers, Q. R.; Freedland, R. A. Relative importance of kidney and liver in synthesis of arginine by the rat. Am. J. Physiol., 1973, 224(1), 127-129.
29. Wu, G. Intestinal mucosal amino acid catabolism. J. Nutr., 1998, 128(8), 1249-1252.
30. Walker, J. B. Creatine: biosynthesis, regulation, and function. Adv. Enzymol. Relat. Areas Mol. Biol., 1979, 50, 177-242.
31. Persky, A. M.; Brazeau, G. A. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol. Rev., 2001, 53(2), 161-176.
32. Wyss, M.; Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev., 2000, 80(3), 1107-1213.
33. Jahangir, E.; Vita, J. A.; Handy, D.; Holbrook, M.; Palmisano, J.; Beal, R.; Loscalzo, J.; Eberhardt, R. T. The effect of L-arginine and creatine on vascular function and homocysteine metabolism. Vasc. Med., 2009, 14(3), 239-248.
34. Taes, Y. E.; Delanghe, J. R.; De Vriese, A. S.; Rombaut, R.; Van Camp, J.; Lameire, N. H. Creatine supplementation decreases homocysteine in an animal model of uremia. Kidney Int., 2003, 64(4), 1331-1337.
35. Derave, W.; Marescau, B.; Vanden Eede, E.; Eijnde, B. O.; De Deyn, P. P.; Hespel, P. Plasma guanidino compounds are altered by oral creatine supplementation in healthy humans. J. Appl. Physiol., 2004, 97(3), 852-857.
36. Wu, G. Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs. Am. J. Physiol., 1997, 272(6 Pt 1), G1382-1390.
37. Jia, Y. X.; Pan, C. S.; Yang, J. H.; Liu, X. H.; Yuan, W. J.; Zhao, J.; Tang, C. S.; Qi, Y. F. Altered L-arginine/nitric oxide synthase/nitric oxide pathway in the vascular adventitia of rats with sepsis. Clin Exp Pharmacol Physiol., 2006, 33(12), 1202-1208.
38. Berkowitz, D. E.; White, R.; Li, D.; Minhas, K. M.; Cernetich, A.; Kim, S.; Burke, S.; Shoukas, A. A.; Nyhan, D.; Champion, H. C.; Hare, J. M. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation, 2003, 108(16), 2000-2006.
39. Chicoine, L. G.; Paffett, M. L.; Young, T. L.; Nelin, L. D. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287(1), L60-68.
40. Hein, T. W.; Zhang, C.; Wang, W.; Chang, C. I.; Thengchaisri, N.; Kuo, L. Ischemia-reperfusion selectively impairs nitric oxidemediated dilation in coronary arterioles: counteracting role of arginase. FASEB J., 2003, 17(15), 2328-2330.
41. Xu, W.; Kaneko, F. T.; Zheng, S.; Comhair, S. A.; Janocha, A. J.; Goggans, T.; Thunnissen, F. B.; Farver, C.; Hazen, S. L.; Jennings, C.; Dweik, R. A.; Arroliga, A. C.; Erzurum, S. C. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J., 2004, 18(14), 1746-1748.
42. Zhang, C.; Hein, T. W.; Wang, W.; Chang, C. I.; Kuo, L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J., 2001, 15(7), 1264-1266.
43. Zhang, C.; Hein, T. W.; Wang, W.; Miller, M. W.; Fossum, T. W.; McDonald, M. M.; Humphrey, J. D.; Kuo, L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension, 2004, 44(6), 935-943.
44. Soskic, S. S.; Dobutovic, B. D.; Sudar, E. M.; Obradovic, M. M.; Nikolic, D. M.; Djordjevic, J. D.; Radak, D. J.; Mikhailidis, D. P.; Isenovic, E. R. Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. Open Cardiovasc Med. J., 2011, 5, 153-163.
45. Zakula, Z.; Koricanac, G.; Putnikovic, B.; Markovic, L.; Isenovic, E. R. Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes. Med. Hypotheses, 2007, 69(2), 302-306.
46. Yang, Z.; Ming, X. F. Arginase: the emerging therapeutic target for vascular oxidative stress and inflammation. Front Immunol., 2013, 4, 149.
47. Forstermann, U.; Munzel, T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation, 2006, 113(13), 1708-1714.
48. Stroes, E.; Kastelein, J.; Cosentino, F.; Erkelens, W.; Wever, R.; Koomans, H.; Luscher, T.; Rabelink, T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest., 1997, 99(1), 41-46.
49. Heitzer, T.; Krohn, K.; Albers, S.; Meinertz, T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia, 2000, 43(11), 1435-1438.
50. Higashi, Y.; Sasaki, S.; Nakagawa, K.; Fukuda, Y.; Matsuura, H.; Oshima, T.; Chayama, K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens, 2002, 15(4 Pt 1), 326-332.
51. Rafikov, R.; Fonseca, F. V.; Kumar, S.; Pardo, D.; Darragh, C.; Elms, S.; Fulton, D.; Black, S. M. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J. Endocrinol., 2011, 210(3), 271-284.
52. Wu, G.; Meininger, C. J. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am. J. Physiol., 1995, 269(4 Pt 2), H1312-1318.
53. Tousoulis, D.; Antoniades, C.; Tentolouris, C.; Goumas, G.; Stefanadis, C.; Toutouzas, P. L-arginine in cardiovascular disease: dream or reality? Vasc. Med., 2002, 7(3), 203-211.
54. Sudar, E.; Dobutovic, B.; Soskic, S.; Mandusic, V.; Zakula, Z.; Misirkic, M.; Vucicevic, L.; Janjetovic, K.; Trajkovic, V.; Mikhailidis, D. P.; Isenovic, E. R. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. J. Physiol. Biochem., 2011, 67(2), 195-204.
55. Arnal, J. F.; el Amrani, A. I.; Chatellier, G.; Menard, J.; Michel, J. B. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension, 1993, 22(3), 380-387.
56. Numaguchi, K.; Egashira, K.; Takemoto, M.; Kadokami, T.; Shimokawa, H.; Sueishi, K.; Takeshita, A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension, 1995, 26(6 Pt 1), 957-962.
57. LaPointe, M. C.; Isenovic, E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension, 1999, 33(1 Pt 2), 276-282.
58. Stojiljkovic, M.; Zakula Z; Koricanac, G.; Milosavljevic, T.; Tepavcevic, S.; Sudar, E.; Isenovic, E. R. Regulation of Cardiac Nitric Oxide Synthase in Acute Type I Diabetes: Modulation of LArginine Availability and Arginase Activity 2012, p. 1-9.
59. Kypreos, K. E.; Zafirovic, S.; Petropoulou, P. I.; Bjelogrlic, P.; Resanovic, I.; Traish, A.; Isenovic, E. R. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J. Cardiovasc. Pharmacol. Ther., 2014, 19(3), 256-268.
60. Dobutovic, B.; Smiljanic, K.; Soskic, S.; Dungen, H.-D.; Isenovic, E. R. Nitric Oxide and its Role in Cardiovascular Diseases. The Open Nitric Oxide J., 2011, 3, 65-71.
61. Grisham, M. B.; Jourd'Heuil, D.; Wink, D. A. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am. J. Physiol., 1999, 276(2 Pt 1), G315-321.
62. Mayer, B.; Hemmens, B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci., 1997, 22(12), 477-481.
63. Dalsgaard, T.; Kroigaard, C.; Simonsen, U. Calcium-activated potassium channels-a therapeutic target for modulating nitric oxide in cardiovascular disease? Expert Opin Ther. Targets, 2010, 14(8), 825-837.
64. Palmer, R. M.; Ashton, D. S.; Moncada, S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 1988, 333(6174), 664-666.
65. Flammer, A. J.; Luscher, T. F. Three decades of endothelium research: from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases. Swiss Med. Wkly, 2010, 140, w13122.
66. Boerrigter, G.; Burnett, J. C., Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev., 2007, 25(1), 30-45.
67. Mayer, B.; Schrammel, A.; Klatt, P.; Koesling, D.; Schmidt, K. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. Dependence on glutathione and possible role of S-nitrosation. J. Biol. Chem., 1995, 270(29), 17355-17360.
68. Bian, K.; Doursout, M. F.; Murad, F. Vascular system: role of nitric oxide in cardiovascular diseases. J. Clin. Hypertens (Greenwich), 2008, 10(4), 304-310.
69. Hobbs, A. J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol. Sci., 1997, 18(12), 484-491.
70. Naseem, K. M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med., 2005, 26(1-2), 33-65.
71. Napoli, C.; Ignarro, L. J. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch. Pharm. Res., 2009, 32(8), 1103-1108.
72. Zago, A. S.; Zanesco, A. Nitric oxide, cardiovascular disease and physical exercise. Arq. Bras. Cardiol., 2006, 87(6), e264-270.
73. Desjardins, F.; Balligand, J. L. Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin. Belg., 2006, 61(6), 326-334.
74. Sarkar, R.; Meinberg, E. G.; Stanley, J. C.; Gordon, D.; Webb, R. C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ. Res., 1996, 78(2), 225-230.
75. Sarkar, R.; Webb, R. C. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. J. Vasc. Res., 1998, 35(3), 135-142.
76. Luscher, T. F.; Vanhoutte, P. M. The Endothelium, Taylor & Francis: 1990.
77. Bogle, R. G.; Baydoun, A. R.; Pearson, J. D.; Moncada, S.; Mann, G. E. L-arginine transport is increased in macrophages generating nitric oxide. Biochem. J., 1992, 284(Pt 1), 15-18.
78. Beckman, J. S.; Koppenol, W. H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol., 1996, 271(5 Pt 1), C1424-1437.
79. Forstermann, U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch., 2010, 459(6), 923-939.
80. Sibal, L.; Agarwal, S. C.; Home, P. D.; Boger, R. H. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr. Cardiol. Rev., 2010, 6(2), 82-90.
81. McDonald, K. K.; Zharikov, S.; Block, E. R.; Kilberg, M. S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J. Biol. Chem., 1997, 272(50), 31213-31216.
82. Bode-Boger, S. M.; Scalera, F.; Ignarro, L. J. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol. Ther., 2007, 114(3), 295-306.
83. Rees, D. D.; Palmer, R. M.; Schulz, R.; Hodson, H. F.; Moncada, S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol., 1990, 101(3), 746-752.
84. Maxwell, A. J.; Cooke, J. P. Cardiovascular effects of L-arginine. Curr. Opin Nephrol. Hypertens, 1998, 7(1), 63-70.
85. Nagase, S.; Takemura, K.; Ueda, A.; Hirayama, A.; Aoyagi, K.; Kondoh, M.; Koyama, A. A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D-or L-arginine. Biochem. Biophys. Res. Commun., 1997, 233(1), 150-153.
86. Walter, R.; Mark, M.; Reinhart, W. H. Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro. Biochem. Biophys. Res. Commun., 2000, 269(3), 687-691.
87. Wascher, T. C.; Posch, K.; Wallner, S.; Hermetter, A.; Kostner, G. M.; Graier, W. F. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase? Biochem. Biophys. Res. Commun., 1997, 234(1), 35-38.
88. Xie, L.; Gross, S. S. Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulantinduced NO production. J. Biol. Chem., 1997, 272(26), 16624-16630.
89. Schott, C. A.; Gray, G. A.; Stoclet, J. C. Dependence of endotoxininduced vascular hyporeactivity on extracellular L-arginine. Br. J. Pharmacol., 1993, 108(1), 38-43.
90. Closs, E. I.; Scheld, J. S.; Sharafi, M.; Forstermann, U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol. Pharmacol., 2000, 57(1), 68-74.
91. Nicholson, B.; Manner, C. K.; Kleeman, J.; MacLeod, C. L. Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J. Biol. Chem., 2001, 276(19), 15881-15885.
92. Chaturvedi, R.; Asim, M.; Lewis, N. D.; Algood, H. M.; Cover, T. L.; Kim, P. Y.; Wilson, K. T. L-arginine availability regulates inducible nitric oxide synthase-dependent host defense against Helicobacter pylori. Infect. Immun., 2007, 75(9), 4305-4315.
93. Boger, R. H. [Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data]. Dtsch. Med. Wochenschr., 2004, 129(15), 820-824.
94. Miyazaki, H.; Matsuoka, H.; Cooke, J. P.; Usui, M.; Ueda, S.; Okuda, S.; Imaizumi, T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation, 1999, 99(9), 1141-1146.
95. Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet., 1992, 339(8793), 572-575.
96. Boger, R. H.; Ron, E. S. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern. Med. Rev., 2005, 10(1), 14-23.
97. Boger, R. H. The pharmacodynamics of L-arginine. J. Nutr., 2007, 137(6 Suppl 2), 1650S-1655S.
98. Hecker, M.; Sessa, W. C.; Harris, H. J.; Anggard, E. E.; Vane, J. R. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc. Natl. Acad. Sci. U.S.A., 1990, 87(21), 8612-8616.
99. Sessa, W. C.; Hecker, M.; Mitchell, J. A.; Vane, J. R. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proc. Natl. Acad. Sci. U.S.A., 1990, 87(21), 8607-8611.
100. Arnal, J. F.; Munzel, T.; Venema, R. C.; James, N. L.; Bai, C. L.; Mitch, W. E.; Harrison, D. G. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. J. Clin. Invest., 1995, 95(6), 2565-2572.
101. Merimee, T. J.; Rabinowitz, D.; Riggs, L.; Burgess, J. A.; Rimoin, D. L.; McKusick, V. A. Plasma growth hormone after arginine infusion. Clinical experiences. N. Engl. J. Med., 1967, 276(8), 434-439.
102. Schmidt, H. H.; Warner, T. D.; Ishii, K.; Sheng, H.; Murad, F. Insulin secretion from pancreatic B cells caused by L-argininederived nitrogen oxides. Science, 1992, 255(5045), 721-723.
103. Bode-Boger, S. M.; Boger, R. H.; Loffler, M.; Tsikas, D.; Brabant, G.; Frolich, J. C. L-arginine stimulates NO-dependent vasodilation in healthy humans--effect of somatostatin pretreatment. J. Investig Med., 1999, 47(1), 43-50.
104. Giugliano, D.; Marfella, R.; Verrazzo, G.; Acampora, R.; Coppola, L.; Cozzolino, D.; D'Onofrio, F. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J. Clin. Invest., 1997, 99(3), 433-438.
105. Boger, R. H.; Skamira, C.; Bode-Boger, S. M.; Brabant, G.; von zur Muhlen, A.; Frolich, J. C. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J. Clin. Invest., 1996, 98(12), 2706-2713.
106. Osterziel, K. J.; Bode-Boger, S. M.; Strohm, O.; Ellmer, A. E.; Bit-Avragim, N.; Hanlein, D.; Ranke, M. B.; Dietz, R.; Boger, R. H. Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res., 2000, 45(2), 447-453.
107. Calver, A.; Collier, J.; Leone, A.; Moncada, S.; Vallance, P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J. Hum. Hypertensm, 1993, 7(2), 193-194.
108. Wu, G.; Meininger, C. J. Arginine nutrition and cardiovascular function. J Nutr. 2000, 130(11), 2626-2629.
109. Higashi, Y.; Oshima, T.; Ozono, R.; Matsuura, H.; Kambe, M.; Kajiyama, G. Effect of L-arginine infusion on systemic and renal hemodynamics in hypertensive patients. Am. J. Hypertens, 1999, 12(1 Pt 1), 8-15.
110. Maxwell, A. J.; Anderson, B.; Zapien, M. P.; Cooke, J. P. Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc. Drugs Ther., 2000, 14(3), 309-316.
111. Crenn, P.; Coudray-Lucas, C.; Thuillier, F.; Cynober, L.; Messing, B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology, 2000, 119(6), 1496-1505.
112. Pita, A. M.; Wakabayashi, Y.; Fernandez-Bustos, M. A.; Virgili, N.; Riudor, E.; Soler, J.; Farriol, M. Plasma urea-cycle-related amino acids, ammonium levels, and urinary orotic acid excretion in short-bowel patients managed with an oral diet. Clin. Nutr., 2003, 22(1), 93-98.
113. Wasa, M.; Takagi, Y.; Sando, K.; Harada, T.; Okada, A. Long-term outcome of short bowel syndrome in adult and pediatric patients. JPEN J. Parenter Enteral. Nutr., 1999, 23(5 Suppl), S110-112.
114. Kritchevsky, D. Dietary protein and atherosclerosis. Atherosclerosis, 1983, 49(2), 209-210.
115. Cooke, J. P. Is atherosclerosis an arginine deficiency disease? J. Investig Med., 1998, 46(8), 377-380.
116. Aji, W.; Ravalli, S.; Szabolcs, M.; Jiang, X. C.; Sciacca, R. R.; Michler, R. E.; Cannon, P. J. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation, 1997, 95(2), 430-437.
117. Cooke, J. P.; Singer, A. H.; Tsao, P.; Zera, P.; Rowan, R. A.; Billingham, M. E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest., 1992, 90(3), 1168-1172.
118. Boger, R. H.; Bode-Boger, S. M.; Kienke, S.; Stan, A. C.; Nafe, R.; Frolich, J. C. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterolfed rabbits. Atherosclerosis, 1998, 136(1), 67-77.
119. Susic, D.; Varagic, J.; Frohlich, E. D. Isolated systolic hypertension in elderly WKY is reversed with L-arginine and ACE inhibition. Hypertension, 2001, 38(6), 1422-1426.
120. Susic, D.; Francischetti, A.; Frohlich, E. D. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension, 1999, 33(1 Pt 2), 451-455.
121. Dumont, Y.; D'Amours, M.; Lebel, M.; Lariviere, R. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol. Dial. Transplant., 2001, 16(4), 746-754.
122. Lee, C. W.; Li, D.; Channon, K. M.; Paterson, D. J. L-arginine supplementation reduces cardiac noradrenergic neurotransmission in spontaneously hypertensive rats. J. Mol. Cell Cardiol., 2009, 47(1), 149-155.
123. Ohta, K.; Hirata, Y.; Shichiri, M.; Kanno, K.; Emori, T.; Tomita, K.; Marumo, F. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int., 1991, 39(2), 307-311.
124. Boulanger, C.; Luscher, T. F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest., 1990, 85(2), 587-590.
125. Bocchi, E. A.; Vilella de Moraes, A. V.; Esteves-Filho, A.; Bacal, F.; Auler, J. O.; Carmona, M. J.; Bellotti, G.; Ramires, A. F. Larginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin. Cardiol., 2000, 23(3), 205-210.
126. Koifman, B.; Wollman, Y.; Bogomolny, N.; Chernichowsky, T.; Finkelstein, A.; Peer, G.; Scherez, J.; Blum, M.; Laniado, S.; Iaina, A. et al. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. J. Am. Coll. Cardiol., 1995, 26(5), 1251-1256.
127. Adams, M. R.; McCredie, R.; Jessup, W.; Robinson, J.; Sullivan, D.; Celermajer, D. S. Oral L-arginine improves endotheliumdependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis, 1997, 129(2), 261-269.
128. Blum, A.; Hathaway, L.; Mincemoyer, R.; Schenke, W. H.; Kirby, M.; Csako, G.; Waclawiw, M. A.; Panza, J. A.; Cannon, R. O., 3rd. Oral L-arginine in patients with coronary artery disease on medical management. Circulation, 2000, 101(18), 2160-2164.
129. Schulman, S. P.; Becker, L. C.; Kass, D. A.; Champion, H. C.; Terrin, M. L.; Forman, S.; Ernst, K. V.; Kelemen, M. D.; Townsend, S. N.; Capriotti, A.; Hare, J. M.; Gerstenblith, G. Larginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA, 2006, 295(1), 58-64.
130. Clarkson, P.; Adams, M. R.; Powe, A. J.; Donald, A. E.; McCredie, R.; Robinson, J.; McCarthy, S. N.; Keech, A.; Celermajer, D. S.; Deanfield, J. E. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J. Clin. Invest., 1996, 97(8), 1989-1994.
131. Bode-Boger, S. M.; Muke, J.; Surdacki, A.; Brabant, G.; Boger, R. H.; Frolich, J. C. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc. Med., 2003, 8(2), 77-81.
132. Ast, J.; Jablecka, A.; Bogdanski, P.; Smolarek, I.; Krauss, H.; Chmara, E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med. Sci. Monit., 2010, 16(5), 266-271.
133. Bogdanski, P.; Szulinska, M.; Suliburska, J.; Pupek-Musialik, D.; Jablecka, A.; Witmanowski, H. Supplementation with L-arginine favorably influences plasminogen activator inhibitor type 1 concentration in obese patients. A randomized, double blind trial. J. Endocrinol. Invest., 2013, 36(4), 221-226.
134. Boger, R. H. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr. Opin Clin. Nutr. Metab. Care, 2008, 11(1), 55-61.
135. Lerman, A.; Burnett, J. C., Jr.; Higano, S. T.; McKinley, L. J.; Holmes, D. R., Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation, 1998, 97(21), 2123-2128.
136. Piatti, P. M.; Monti, L. D.; Valsecchi, G.; Magni, F.; Setola, E.; Marchesi, F.; Galli-Kienle, M.; Pozza, G.; Alberti, K. G. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care, 2001, 24(5), 875-880.
137. Wilson, A. M.; Harada, R.; Nair, N.; Balasubramanian, N.; Cooke, J. P. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation, 2007, 116(2), 188-195.
138. Chen, J.; Kuhlencordt, P.; Urano, F.; Ichinose, H.; Astern, J.; Huang, P. L. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb. Vasc. Biol., 2003, 23(1), 97-103.
139. Liang, F.; Gao, E.; Tao, L.; Liu, H.; Qu, Y.; Christopher, T. A.; Lopez, B. L.; Ma, X. L. Critical timing of L-arginine treatment in post-ischemic myocardial apoptosis-role of NOS isoforms. Cardiovasc Res., 2004, 62(3), 568-577.
140. Takeuchi, K.; McGowan, F. X.; Danh, H. C.; Glynn, P.; Simplaceanu, E.; del Nido, P. J. Direct detrimental effects of Larginine upon ischemia--reperfusion injury to myocardium. J. Mol. Cell Cardiol., 1995, 27(7), 1405-1414.
141. Wang, X.; Liang, F.; Jiao, X.; Liu, L.; Bai, X.; Li, M.; Zhi, J.; Liu, H. Diverse effects of L-arginine on cardiac function of rats subjected to myocardial ischemia and reperfusion in vivo. Acta Biochim Biophys Sin (Shanghai), 2007, 39(3), 201-207.
142. Mungrue, I. N.; Gros, R.; You, X.; Pirani, A.; Azad, A.; Csont, T.; Schulz, R.; Butany, J.; Stewart, D. J.; Husain, M. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J. Clin. Invest., 2002, 109(6), 735-743.
143. Lundberg, J. O.; Gladwin, M. T.; Weitzberg, E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat. Rev. Drug Discov., 2015, 14(9), 623-41.
144. Lobo, V.; Patil, A.; Phatak, A.; Chandra, N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev., 2010, 4(8), 118-126.
145. Loscalzo, J. Adverse effects of supplemental L-arginine in atherosclerosis: consequences of methylation stress in a complex catabolism? Arterioscler Thromb Vasc. Biol., 2003, 23(1), 3-5.
146. Mizunuma, T.; Kawamura, S.; Kishino, Y. Effects of injecting excess arginine on rat pancreas. J. Nutr., 1984, 114(3), 467-471.
147. Hegyi, P.; Rakonczay, Z., Jr.; Sari, R.; Gog, C.; Lonovics, J.; Takacs, T.; Czako, L. L-arginine-induced experimental pancreatitis. World J. Gastroenterol., 2004, 10(14), 2003-2009.
148. Kui, B.; Balla, Z.; Vegh, E. T.; Pallagi, P.; Venglovecz, V.; Ivanyi, B.; Takacs, T.; Hegyi, P.; Rakonczay, Z., Jr. Recent advances in the investigation of pancreatic inflammation induced by large doses of basic amino acids in rodents. Lab. Invest., 2014, 94(2), 138-149.
149. Czako, L.; Takacs, T.; Varga, I. S.; Hai, D. Q.; Tiszlavicz, L.; Hegyi, P.; Mandi, Y.; Matkovics, B.; Lonovics, J. The pathogenesis of L-arginine-induced acute necrotizing pancreatitis: inflammatory mediators and endogenous cholecystokinin. J. Physiol. Paris., 2000, 94(1), 43-50.
150. Takacs, T.; Czako, L.; Morschl, E.; Laszlo, F.; Tiszlavicz, L.; Rakonczay, Z., Jr.; Lonovics, J. The role of nitric oxide in edema formation in L-arginine-induced acute pancreatitis. Pancreas, 2002, 25(3), 277-282.
151. Czako, L.; Takacs, T.; Varga, I. S.; Tiszlavicz, L.; Hai, D. Q.; Hegyi, P.; Matkovics, B.; Lonovics, J. Involvement of oxygenderived free radicals in L-arginine-induced acute pancreatitis. Dig. Dis. Sci., 1998, 43(8), 1770-1777.
152. Saka, M.; Tuzun, A.; Ates, Y.; Bagci, S.; Karaeren, N.; Dagalp, K. Acute pancreatitis possibly due to arginine use: a case report. Turk J. Gastroenterol., 2004, 15(1), 56-58.
153. Martina, V.; Masha, A.; Gigliardi, V. R.; Brocato, L.; Manzato, E.; Berchio, A.; Massarenti, P.; Settanni, F.; Della Casa, L.; Bergamini, S.; Iannone, A. Long-term N-acetylcysteine and Larginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care, 2008, 31(5), 940-944.
154. Lee, W. H.; Gounarides, J. S.; Roos, E. S.; Wolin, M. S. Influence of peroxynitrite on energy metabolism and cardiac function in a rat ischemia-reperfusion model. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(4), H1385-1395.
155. Heitzer, T.; Just, H.; Munzel, T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation, 1996, 94(1), 6-9.
156. Cabassi, A.; Dumont, E. C.; Girouard, H.; Bouchard, J. F.; Le Jossec, M.; Lamontagne, D.; Besner, J. G.; de Champlain, J. Effects of chronic N-acetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J. Hypertens, 2001, 19(7), 1233-1244.
157. Castillo, L.; Beaumier, L.; Ajami, A. M.; Young, V. R. Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling. Proc. Natl. Acad. Sci. U.S.A., 1996, 93(21), 11460-11465.
158. Beaumier, L.; Castillo, L.; Ajami, A. M.; Young, V. R. Urea cycle intermediate kinetics and nitrate excretion at normal and "therapeutic" intakes of arginine in humans. Am. J. Physiol., 1995, 269(5 Pt 1), E884-896.
159. Chang, C. I.; Liao, J. C.; Kuo, L. Arginase modulates nitric oxide production in activated macrophages. Am. J. Physiol., 1998, 274(1 Pt 2), H342-348.
160. Dobutovic, B.; Sudar, E.; Tepavcevic, S.; Djordjevic, J.; Djordjevic, A.; Radojcic, M.; Isenovic, E. R. Effects of ghrelin on protein expression of antioxidative enzymes and iNOS in the rat liver. Arch. Med. Sci., 2014, 10(4), 806-816.
161. Sudar, E.; Obradovic, M.; Zafirovic, S.; Soskic, S.; Knezevic Rajic, I.; Isenovic, E.R. Role of Erk 1/2 and Akt in the Regulation of eNOS and iNOS In Cardiovascular System. Med. Investigat., 2012, 46(3), 35-42.